These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22610713)

  • 1. Tigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for Enterobacteriaceae.
    Pasteran F; Lucero C; Rapoport M; Guerriero L; Barreiro I; Albornoz E; Veliz O; Corso A
    J Infect Dev Ctries; 2012 May; 6(5):452-6. PubMed ID: 22610713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline.
    Livermore DM; Warner M; Mushtaq S; Doumith M; Zhang J; Woodford N
    Int J Antimicrob Agents; 2011 May; 37(5):415-9. PubMed ID: 21429716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
    Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
    Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of antibiotic synergy for NDM-1-producing Enterobacteriaceae.
    Berçot B; Poirel L; Dortet L; Nordmann P
    J Antimicrob Chemother; 2011 Oct; 66(10):2295-7. PubMed ID: 21807739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany.
    Kaase M; Szabados F; Anders A; Gatermann SG
    J Clin Microbiol; 2014 Jun; 52(6):1893-7. PubMed ID: 24648559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin.
    Endimiani A; Patel G; Hujer KM; Swaminathan M; Perez F; Rice LB; Jacobs MR; Bonomo RA
    Antimicrob Agents Chemother; 2010 Jan; 54(1):526-9. PubMed ID: 19901089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
    Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of the EUCAST disc diffusion method and two MIC methods in detection of Enterobacteriaceae with reduced susceptibility to meropenem: the NordicAST CPE study.
    Haldorsen B; Giske CG; Hansen DS; Helgason KO; Kahlmeter G; Löhr IH; Matuschek E; Österblad M; Rantakokko-Jalava K; Wang M; Småbrekke L; Samuelsen Ø; Sundsfjord A;
    J Antimicrob Chemother; 2018 Oct; 73(10):2738-2747. PubMed ID: 30053113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC method.
    Hope R; Parsons T; Mushtaq S; James D; Livermore DM
    J Antimicrob Chemother; 2007 Oct; 60(4):770-4. PubMed ID: 17704517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of temocillin and 15 other agents, including fosfomycin and colistin, against Enterobacteriaceae in Hong Kong.
    Ip M; Lai CK; Fung KSC; Wong KT; Zhu C; Van de Velde S; Tsang DN; Hawkey P
    Eur J Clin Microbiol Infect Dis; 2017 Dec; 36(12):2491-2494. PubMed ID: 28840351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
    Castanheira M; Sader HS; Deshpande LM; Fritsche TR; Jones RN
    Antimicrob Agents Chemother; 2008 Feb; 52(2):570-3. PubMed ID: 18070960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibilities of clinical isolates of carbapenemase-producing Enterobacteriaceae to fosfomycin and tigecycline.
    Choudhury S; Yeng JL; Krishnan PU
    Clin Microbiol Infect; 2015 Oct; 21(10):e75-6. PubMed ID: 26086572
    [No Abstract]   [Full Text] [Related]  

  • 13. Influence of media and testing methodology on susceptibility to tigecycline of Enterobacteriaceae with reported high tigecycline MIC.
    Torrico M; González N; Giménez MJ; Alou L; Sevillano D; Navarro D; Díaz-Antolín MP; Larrosa N; Aguilar L; Garcia-Escribano N
    J Clin Microbiol; 2010 Jun; 48(6):2243-6. PubMed ID: 20351208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to nemonoxacin, tigecycline, fosfomycin and other antimicrobial agents.
    Hsu MS; Liao CH; Liu CY; Yang CJ; Huang YT; Hsueh PR
    Int J Antimicrob Agents; 2011 Mar; 37(3):276-8. PubMed ID: 21269811
    [No Abstract]   [Full Text] [Related]  

  • 15. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp.
    Jones RN; Ferraro MJ; Reller LB; Schreckenberger PC; Swenson JM; Sader HS
    J Clin Microbiol; 2007 Jan; 45(1):227-30. PubMed ID: 17093026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli.
    Vasoo S; Cunningham SA; Cole NC; Kohner PC; Menon SR; Krause KM; Harris KA; De PP; Koh TH; Patel R
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7842-6. PubMed ID: 26392487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of potential old and new drugs against multidrug-resistant gram-negatives.
    Rizek C; Ferraz JR; van der Heijden IM; Giudice M; Mostachio AK; Paez J; Carrilho C; Levin AS; Costa SF
    J Infect Chemother; 2015 Feb; 21(2):114-7. PubMed ID: 25456893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-spectrum β-lactamase-producing Enterobacteriaceae: in vitro susceptibility to fosfomycin, nitrofurantoin and tigecycline.
    Al-Zarouni M; Senok A; Al-Zarooni N; Al-Nassay F; Panigrahi D
    Med Princ Pract; 2012; 21(6):543-7. PubMed ID: 22722224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of tigecycline against multidrug-resistant Enterobacteriaceae isolates from a Belgian hospital.
    Naesens R; Ursi JP; Van Schaeren J; Jeurissen A
    Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):381-4. PubMed ID: 18802728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods.
    Lu CL; Liu CY; Huang YT; Liao CH; Teng LJ; Turnidge JD; Hsueh PR
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4295-301. PubMed ID: 21670185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.